| abstract |
It refers to a macrocyclic derivative compound of formula (I); wherein A1 and A2 independently represent hydrogen or halogen, linear or branched polyhaloalkyl (C1-C6), among others; G represents a group -NR7-, a 1,2,3,4-tetrahydroisoquinoline group optionally substituted with a group T, among others; T represents a hydrogen, a linear or branched alkylene; X represents a (C2-C8) alkylene; Y represents a -CH2- or -CO- group; R3 and R4 are such that: one of the two represents a phenyl group of formula (a), in which W represents a hydroxy group or a phosphate group; Ra, Rb, Rc and Rd represent, independently a hydrogen, a linear or branched (C1-C6) alkyl group. A selected compound is 11-chloro-4- (4-hydroxyphenyl) -1,7,8-trimethyl-4,16,17,23,24,25-hexahydro-1H, 14H-15,18-methane-6, 9- (methene) dibenzo [b, h] pyrazolo [4,3-p] [1,6,11,15] oxatriazacycloicosin-5,14 (8H) -dione, among others. Said compound has pro-apoptotic properties, being useful in the treatment of cancer and autoimmune diseases. It also refers to a preparation process and a pharmaceutical composition comprising said compound. |